What Happened
Dynavax Technologies Corporation DVAX traded up 3.7 percent Wednesday after management announced the Centers for Disease Control and Prevention will recommend HEPLISAV-B as an adult vaccination for hepatitis B.
The official nod from the Advisory Committee on Immunization Practices, which voted unanimously to add the compound to its recommended product list, is significant to Dynavax as it satisfies coverage requirements for some health insurers.
Why It's Important
"With the ACIP's recommendation, HEPLISAV-B has cleared an important milestone needed to position Dynavax to meet our long-term commercial goals,” Dynavax CEO Eddie Gray said in a press release. “Additionally, this recognition emphasizes the important role of HEPLISAV-B in the prevention of hepatitis B infection in adults, reinforcing our belief that our unique two-dose vaccine with demonstrated higher rates of protection versus ENGERIX-B, and a safety profile similar to three-dose vaccines, will become the new standard of care for adults.”
The U.S. Food and Drug Administration had approved HEPLISAV-B in November, prompting momentary stabilization in the otherwise plummeting stock.
What's Next
January saw commercial launch in the U.S., and Dynavax will begin actively selling the vaccine next week.
At time of publication, Dynavax's stock was trading around $17.55 per share.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.